Technology | February 19, 2009

Bard Receives FDA Approval for the LifeStent Peripheral Stent

February 19, 2009 - C. R. Bard Inc. this week said it received pre-market approval (PMA) from the FDA to market the LifeStent FlexStar and FlexStar XL Vascular Stent Systems, which are approved for the treatment of occlusive disease in native superficial femoral arteries (SFA) and proximal popliteal arteries.

Two-year clinical data on the LifeStent vascular stent demonstrated a freedom from target lesion revascularization rate of 78 percent vs. 42 percent (p<.0001 for="" percutaneous="" transluminal="" angioplasty="" alone.="" in="" addition="" the="" device="" exhibited="" a="" low="" fracture="" rate="" of="" percent="" at="" months.="">

“The long-term data recently presented are important because they demonstrate the sustained performance of the LifeStent vascular stent,” said Dr. Barry Katzen, M.D., founder and medical director of Baptist Cardiac and Vascular Institute and co-principal investigator of the LifeStent RESILIENT trial. “Of particular significance to clinicians and patients is the approval of the 170 mm stent, the longest commercially available in the U.S. Henceforth, long and diffuse lesions presenting in the SFA can be effectively treated with a single stent, which should help improve both clinical outcomes and procedural costs.”

Bard said approval of the LifeStent positions it as the only company offering a stent indicated for the treatment of SFA and proximal popliteal disease in the U.S.

For more information:

Related Content

News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 11, 2015
Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new interim analysis from a...
CSI, OPTIMIZE study, peripheral orbital atherectomy system, peripheral artery disease, PAD

Diamondback 360 orbital atherectomy system. Image courtesy of Cardiovascular Systems Inc.

News | Atherectomy Devices| November 03, 2015
Cardiovascular Systems Inc. (CSI) announced last week that the first two patients have been enrolled in its OPTIMIZE,...
Overlay Init